Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Human Reproduction Update

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/humupd/dmt037PMID 24077980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomised controlled trial

  2016cited by this paper
• Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection.

  2013cited by this paper
• Biomarkers of ovarian response: current and future applications.

  2013influential reference
• External validation of anti-Müllerian hormone based prediction of live birth in assisted conception

  2013cited by this paper
• Antral follicle count determines poor ovarian response better than anti-müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles

  2013cited by this paper
• Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients.

  2013cited by this paper
• Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach.

  2013cited by this paper
• Intracycle variation in number of antral follicles stratified by size and in endocrine markers of ovarian reserve in women with normal ovulatory menstrual cycles

  2013cited by this paper
• Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count

  2013cited by this paper
• Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection.

  2013cited by this paper
• Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization

  2012cited by this paper
• Anti-mullerian hormone cut-off values for predicting poor ovarian response to exogenous ovarian stimulation in in-vitro fertilization

  2012cited by this paper
• The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments

  2012cited by this paper
• Data-driven assessment of the human ovarian reserve.

  2012cited by this paper
• Possibilities and limits of ovarian reserve testing in ART.

  2012influential reference
• The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial

  2012cited by this paper
• The poor responder in IVF: is the prognosis always poor?: a systematic review.

  2012cited by this paper
• Clinical application of anti-Müllerian hormone as a predictor of controlled ovarian hyperstimulation outcome

  2012cited by this paper
• The ovarian reserve in mammals: a functional and evolutionary perspective.

  2012cited by this paper
• Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women.

  2012cited by this paper
• Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle‐stimulating hormone starting dose in in vitro fertilisation cycles

  2012cited by this paper
• Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure.

  2012cited by this paper
• Understanding the perceptions of and emotional barriers to infertility treatment: a survey in four European countries.

  2012cited by this paper
• Screening for fetal aneuploidies at 11 to 13 weeks

  2011cited by this paper
• Correlation of ovarian reserve tests with histologically determined primordial follicle number.

  2011cited by this paper
• ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria.

  2011cited by this paper
• Age-specific nomogram for the decline in antral follicle count throughout the reproductive period.

  2011cited by this paper
• The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age

  2011cited by this paper
• New algorithm for OHSS prevention

  2011cited by this paper
• Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries.

  2011cited by this paper
• Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization

  2011cited by this paper
• Anti-Müllerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation.

  2011cited by this paper
• Live birth chances in women with extremely low-serum anti-Mullerian hormone levels.

  2011cited by this paper
• Conventional ovarian stimulation no longer exists: welcome to the age of individualized ovarian stimulation.

  2011cited by this paper
• Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone

  2011cited by this paper
• Anti-Müllerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.

  2011cited by this paper
• Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF.

  2011influential reference
• An OHSS-Free Clinic by segmentation of IVF treatment.

  2011cited by this paper
• A multicentre evaluation of the new Beckman Coulter anti-Müllerian hormone immunoassay (AMH Gen II)

  2011cited by this paper
• Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology

  2011cited by this paper
• Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF.

  2011influential reference
• GnRH agonist for triggering of final oocyte maturation: time for a change of practice?

  2011cited by this paper
• The journey from the old to the new AMH assay: how to avoid getting lost in the values.

  2011cited by this paper
• Serum anti-Müllerian hormone is a better predictor of ovarian response than FSH and age in IVF patients with endometriosis

  2011cited by this paper
• Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles.

  2011cited by this paper
• Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels.

  2011cited by this paper
• Age-related normogram for antral follicle count: McGill reference guide.

  2011cited by this paper
• Using anti‐Müllerian hormone to identify a good prognosis group in women of advanced reproductive age

  2011cited by this paper
• Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction.

  2011cited by this paper
• The interovarian variation in three-dimensional ultrasound markers of ovarian reserve in women undergoing baseline investigation for subfertility.

  2011cited by this paper
• Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles

  2011cited by this paper
• AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis.

  2011influential reference
• Anti-Mullerian hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles

  2011cited by this paper
• Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT).

  2010cited by this paper
• Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.

  2010cited by this paper
• Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients

  2010cited by this paper
• Poor prognosis for ovarian response to stimulation: results of a randomised trial comparing the flare-up GnRH agonist protocol vs. the antagonist protocol

  2010cited by this paper
• A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation.

  2010cited by this paper
• The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation.

  2010cited by this paper
• Development of a second generation anti-Müllerian hormone (AMH) ELISA.

  2010cited by this paper
• Comparison of gonadotropin‐releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients

  2010cited by this paper
• Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF).

  2010cited by this paper
• 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.

  2010cited by this paper
• Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).

  2010cited by this paper
• The antral follicle count: practical recommendations for better standardization.

  2010cited by this paper
• Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction.

  2010cited by this paper
• Preventing ovarian hyperstimulation syndrome: guidance for the clinician.

  2010cited by this paper
• Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.

  2009cited by this paper
• Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program.

  2009cited by this paper
• Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm)

  2009cited by this paper
• Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.

  2009cited by this paper
• Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.

  2009cited by this paper
• Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function.

  2009cited by this paper
• Establishing the intercycle variability of three-dimensional ultrasonographic predictors of ovarian reserve.

  2008cited by this paper
• Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve.

  2008cited by this paper
• Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial

  2008cited by this paper
• Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age.

  2008cited by this paper
• Why do couples drop-out from IVF treatment? A prospective cohort study.

  2008cited by this paper
• Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception.

  2008cited by this paper
• Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation.

  2008cited by this paper
• Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve

  2008cited by this paper
• Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial.

  2008cited by this paper
• Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone.

  2008cited by this paper
• Poor responder protocols for in-vitro fertilization: options and results

  2008cited by this paper
• Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?

  2008cited by this paper
• Relevance of anti-Mullerian hormone measurement in a routine IVF program.

  2008cited by this paper
• Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients.

  2008cited by this paper
• Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.

  2007cited by this paper
• Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population.

  2007cited by this paper
• Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART).

  2007cited by this paper
• Müllerian inhibiting substance is an accurate marker of ovarian response in women of advanced reproductive age undergoing IVF.

  2007cited by this paper
• Sonographic assessment of ovarian reserve. Its correlation with outcome of in vitro fertilization cycles

  2007cited by this paper
• Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment?

  2007cited by this paper
• Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles.

  2007cited by this paper
• Anti-Müllerian hormone as a predictor of IVF outcome.

  2007influential reference
• Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection.

  2007cited by this paper
• Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy.

  2007cited by this paper
• Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review.

  2007cited by this paper
• What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?

  2007influential reference
• A systematic review of tests predicting ovarian reserve and IVF outcome.

  2006cited by this paper

• Acupuncture in patients with the poor ovarian response on IVF-ET: A systematic review and network meta-analysis

  2026cites this paper
• Hormonal Modulation of Keratoconus: A Systematic Review and Screening Strategy for At-Risk Populations.

  2026cites this paper
• Descriptive overview of gene variants potentially affecting female infertility treatments: A systematic review.

  2026cites this paper
• Evaluation of Recombinant Follicle-Stimulating Hormone (rFSH) Plus Recombinant Luteinizing Hormone (rLH) and rFSH Plus Human Menopausal Gonadotropin (HMG) Combination Therapies in Patients With Poor Ovarian Response Undergoing Ovarian Stimulation

  2026cites this paper
• IGF-1 Deficiency Serves as an Integrated Biomarker Pathogenic Driver and Predictor in Poor Ovarian Response.

  2026cites this paper
• Association of serum and follicular fluid thiol/disulfide homeostasis in patients undergoing intracytoplasmic sperm injection

  2025cites this paper
• Nomogram model to predict the risk of moderate to severe ovarian hyperstimulation syndrome of long protocol group in fresh cycle

  2025influential citation
• An overview of anti-Müllerian hormone (AMH) in cattle reproduction and its applications in assisted reproductive technologies.

  2025cites this paper
• Ovarian stimulation protocols in fresh cycles and in elective freeze-all cycles

  2025cites this paper
• Ovarian response in natural cycle, minimal stimulation and conventional IVF protocols in relation to anti-mullerian hormone level - A multi-center study.

  2025cites this paper
• Ovarian Reserve Evaluation Using Anti-Müllerian Hormone Levels Among Subfertile Women

  2025cites this paper
• Morphokinetic embryo behaviour in low-prognosis patients according to the POSEIDON criteria: an analysis of 3326 injected oocytes.

  2025cites this paper
• Integration Analysis of Metabolome and Transcriptome Reveals the Effect of Lipopolysaccharide on Ovary Response to Stimulation

  2025cites this paper
• Factors determining the effectiveness of ARTs: a review of the literature

  2025cites this paper
• Comprehensive mathematical modeling of age-dependent oocyte quality and quantity for predicting live birth rate

  2025cites this paper
• How to enhance prediction of clinical outcomes in poor responders: integrating high-specific assays for anti-mullerian hormone with antral follicle count

  2025cites this paper
• The effect of COVID-19 vaccination on serum levels of anti-Müllerian hormone in women of reproductive age

  2025cites this paper
• Constructing a predictive model for anti-Müllerian hormone levels in reproductive-age women based on transvaginal three-dimensional ultrasound.

  2025cites this paper
• Yardımcı Üreme Tedavisi Sonuçlarında Zayıf Yanıt Veren Olgularda Over Rezerv Belirteçlerinin Öngörü Potansiyeli

  2025cites this paper
• Изменение овариального резерва в процессе комбинированного лечения дифференцированного рака щитовидной железы

  2025cites this paper
• The Evolving Role of Anti-Müllerian Hormone Measurements in Clinical Practice.

  2025cites this paper
• Technical laboratory procedures faced on many oocytes picked up in vitro fertilization cycles

  2025cites this paper
• Risk factors and clinical outcomes of late-onset severe ovarian hyperstimulation syndrome in advanced maternal age women undergoing fresh embryo transfer

  2025cites this paper
• Trend Research of Studies on In Vitro Fertilization from 2013-2023

  2025cites this paper
• Dose-Dependent Modulation of LH Receptor Expression in Human Granulosa Cells and Progesterone Production During Ovarian Stimulation.

  2025cites this paper
• Impact of total motile sperm count on ICSI outcomes in male factor infertility: A retrospective cohort study

  2025cites this paper
• Random start approach in breast cancer patients: are all menstrual cycle phases the same?

  2025cites this paper
• Outcome of In Vitro Fertilization (IVF) Treatment in Infertile Couples-A Retrospective Study

  2025cites this paper
• Correlation between serum AMH, AFC, AND histologically quantified primordial follicles: a prospective study in premenopausal women

  2025cites this paper
• Impact of CKD on Female Reproductive Hormones

  2025cites this paper
• Effectiveness and Safety of Highly Purified Human Menopausal Gonadotropin in Hyper Responder Iraqi Females Undergoing Intracytoplasmic Sperm Injection

  2025cites this paper
• Outcomes of oocyte cryopreservation: an analysis based on age and treatment indications.

  2025cites this paper
• Unexpected hypo-responders in in vitro fertilization: The impact of higher gonadotropin doses on oocyte yield

  2025cites this paper
• Effect of repeated controlled ovarian stimulation on pregnancy outcomes in fresh embryo transfer cycles: a retrospective cohort study

  2025cites this paper
• Does the Timing of Antagonist Treatment Influence Cycle Outcomes in Unexpected Low Responders of POSEIDON Class 1 and 2?

  2025cites this paper
• Fertility Challenges Facing Women with Early-Stage Endometrial Cancer

  2025cites this paper
• Factors influencing oocyte yield and embryo quality in donor IVF cycles: a retrospective cohort study

  2025cites this paper
• Oocyte maturation defect in women undergoing IVF: contributing factors and effects on mature sibling oocyte outcomes

  2025cites this paper
• Tubal occlusion in patients with hydrosalpinx modifies the uterine environment and improves in vitro fertilization outcomes within 7 months

  2025cites this paper
• Clinical outcomes from assisted reproductive technology in predicted hyper-responders: a narrative review.

  2025cites this paper
• Impact of gonadotropin genetic profile and ovarian reserve on controlled ovarian stimulation: data from prospective cohort of the GENOCS trial

  2025cites this paper
• Vitamin-D in Women with Primary Infertility in a Tertiary Care Centre in the Southeast Region of Bangladesh

  2025cites this paper
• Maternal age and progesterone levels at trigger day as independent predictors of clinical pregnancy in poor ovarian responders undergoing IVF/ICSI: a retrospective analysis

  2025cites this paper
• Ovarian sensitivity index-based nomogram for predicting clinical pregnancy outcomes in patients with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection

  2025cites this paper
• Predictive value of AMH in late reproductive age: a retrospective cohort study

  2025cites this paper
• Average gonadotropin dosage per follicle as a predictor of ovarian response

  2025cites this paper
• Distinct post-insemination dynamics between fresh and frozen-derived gametes using testicular sperm

  2025cites this paper
• Dual Impact of Estradiol Fluctuations in the Final Three Days on IVF/ICSI Outcomes: A Retrospective Cohort Analysis

  2025cites this paper
• SINDROME DA HIPERESTIMULAÇÃO OVARIANA: UMA CONSEQUÊNCIAS DO USO DE HORMÔNIOS EM EXCESSO

  2025cites this paper
• A highly sensitive Anti-Müllerian hormone test as a promising tool for follicle growth prediction in primary ovarian insufficiency patients

  2025cites this paper
• Critical factors influencing live birth rates in fresh embryo transfer for IVF: insights from cluster ensemble algorithms

  2025cites this paper
• Association of serum AMH levels with the number of oocytes retrieved in adolescent and young adult women undergoing controlled ovarian stimulation for fertility preservation

  2025cites this paper
• The role of LH in follicle development: from physiology to new clinical implications

  2025cites this paper
• Ovarian function in adolescents and young adults undergoing cancer treatment: biochemical and ultrasound marker analysis

  2025cites this paper
• Autophagy activity is increased in the cumulus cells of women with poor ovarian response.

  2024cites this paper
• Significance of serum AMH and antral follicle count discrepancy for the prediction of ovarian stimulation response in Poseidon criteria patients

  2024cites this paper
• Effects of ovarian response prediction index and follicle-oocyte index on pregnancy outcomes: a retrospective cohort study of 12,218 fresh transfer cycles

  2024cites this paper
• Factors Associated with the Occurrence of 0PN Fertilization in in Vitro Fertilization and its Effects on Embryo Development and Reproductive Outcomes

  2024cites this paper
• Primary sex ratio in euploid embryos of consanguine couples after IVF/ICSI

  2024cites this paper
• Association of serum uric acid with women's ovarian reserve: observational study and Mendelian randomization analyses.

  2024cites this paper
• Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study

  2024cites this paper
• Which Ovarian Reserve Marker is More Reliable in IVF Patients with AMH and AFC Discordance?

  2024cites this paper
• Exploring gonadotropin dosing effects on MII oocyte retrieval in ovarian stimulation

  2024cites this paper
• Heavy Metals and Trajectories of Anti-Müllerian Hormone During the Menopausal Transition.

  2024cites this paper
• Development and validation of a gonadotropin dose selection model for optimized ovarian stimulation in IVF/ICSI: an individual participant data meta-analysis

  2024cites this paper
• Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).

  2024cites this paper
• Reproductive Health in Women with Major β-Thalassemia: Evaluating Ovarian Reserve and Endocrine Complications

  2024cites this paper
• Understanding the implications of follicular output rate (FORT) and follicle to oocyte index (FOI) on human embryo morphokinetics

  2024cites this paper
• Clinical factors associated with unexpected poor or suboptimal response in Poseidon criteria patients.

  2024cites this paper
• MicroRNAs as Biomarkers and Therapeutic Targets in Female Infertility

  2024cites this paper
• Anti-Mullerian Hormone and Antral Follicle Count Thresholds for Hyper-Response Risk Assessment in IVF: A HERA Consensus Study.

  2024cites this paper
• Ovarian reserve, metabolic and neuroendocrine profiles of cadets from Air Force Academy: a pilot study.

  2024cites this paper
• FSH/LH co-stimulation in Advanced Maternal Age (AMA) and hypo-responder patients – Arabian gulf delphi consensus group

  2024cites this paper
• Comparative analysis of long versus short co-incubation of gametes on post-insemination outcomes and embryo morphokinetics.

  2024cites this paper
• Follicular fluid and serum Prostaglandin D2 level as a biomarker for ovarian reserve and response in IVF protocol

  2024cites this paper
• Assessing the clinical value of day 7 blastocysts: a predictive model for preimplantation genetic testing for aneuploidy (PGT-A) cycles

  2024cites this paper
• Patients with low prognosis in ART: a Delphi consensus to identify potential clinical implications and measure the impact of POSEIDON criteria

  2024cites this paper
• Expert Opinion on Refined and Extended Key Performance Indicators for Individualized Ovarian Stimulation for ART.

  2024cites this paper
• Steady morphokinetic progression is an independent predictor of live birth: a descriptive reference for euploid embryos

  2024cites this paper
• A Comparative Study of Fresh versus Frozen Embryo Transfer and their Outcomes in Patients with Polycystic Ovarian Syndrome

  2024cites this paper
• Fundamentals, biological, medical and social aspects of assisted reproductive technologies: history of creation, current state, prospects

  2024cites this paper
• A new decision-support tool in a multi-center randomized trial for personalized, optimized, and simplified fertility treatment in non-PCOS patients

  2024cites this paper
• Diminished ovarian reserve associates with pregnancy and birth outcomes after IVF: a retrospective cohort study

  2024cites this paper
• Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Efecto gonadotóxico de los tratamientos oncológicos en mujeres adolescentes y jóvenes adultas

  2024cites this paper
• Ovarian sensitivity index affects clinical pregnancy and live birth rates in gonadotropin-releasing hormone agonist and antagonist in vitro fertilization cycles

  2024cites this paper
• Metagenomic analysis revealed the association between gut microbiota and different ovary responses to controlled ovarian stimulation

  2024cites this paper
• Advancements in Gynecology: A Comprehensive Review of Emerging Research and Innovations

  2024cites this paper
• The use of oral GnRH antagonists to inhibit the LH surge in women undergoing ovarian stimulation for in vitro fertilization

  2024cites this paper
• Age Related Antral Follicle Count Nomogram for Egyptian Women

  2024cites this paper
• [Fertility preservation and hematopoietic stem cell transplantation (SFGM-TC)].

  2024cites this paper
• Excisional surgery versus ablative surgery for ovarian endometrioma.

  2024cites this paper
• Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women

  2024cites this paper
• The impact of maternal nutrition during preconception, pregnancy and lactation on the ovarian reserve of offspring: a narrative review

  2024cites this paper
• GnRH agonist early follicular challenge test as a predictor of ovarian response in antagonist cycles for fertility preservation

  2024cites this paper
• Anti-Müllerian hormone levels are associated with time to pregnancy in a prospective cohort study of 3,150 women.

  2024cites this paper
• The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials

  2024cites this paper
• Verification of the utility of the gonadotropin starting dose calculator in progestin‐primed ovarian stimulation: A comparison of empirical and calculated controlled ovarian stimulation

  2024cites this paper
• The best ovarian reserve marker to predict ovarian response following controlled ovarian hyperstimulation: a systematic review and meta-analysis

  2024cites this paper
• Assisted Reproductive Technology Outcomes in Women with Normal Ovarian Response Receiving Recombinant Luteinizing Hormone/Human Menopausal Gonadotropin: An Observational Study

  2024cites this paper